| Trial ID: | L4470 |
| Source ID: | NCT01451918
|
| Associated Drug: |
Resveratrol
|
| Title: |
Regulation of Intestinal and Hepatic Lipoprotein Secretion by Resveratrol
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Dyslipidaemia|Insulin Resistance
|
| Interventions: |
DRUG: Resveratrol
|
| Outcome Measures: |
Primary: Examine the effect of resveratrol on ApoB 100 and ApoB 48 production in humans, 10 hour lipoprotein turnover study as described above following 2 weeks treatment with resveratrol or placebo., 2 weeks | Secondary: Assess the change in insulin sensitivity with resveratrol treatment, HOMA-IR calculated from fasting insulin and fasting glucose will be used to assess change in insulin sensitivity before and after 2 weeks of resveratrol treatment., 2 weeks
|
| Sponsor/Collaborators: |
Sponsor: University Health Network, Toronto | Collaborators: Canadian Institutes of Health Research (CIHR)
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
8
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2011-10
|
| Completion Date: |
2013-09
|
| Results First Posted: |
|
| Last Update Posted: |
2014-05-06
|
| Locations: |
Toronto General Hospital, Toronto, Ontario, Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT01451918
|
